Clinical Commissioning Policy: Pasireotide diaspartate: an injectable medical therapy for the treatment of Cushings’ Disease

Document first published:: 12 December 2016
Page updated:: 27 September 2017
Topic:: Commissioning, Specialised commissioning
Publication type:: Policy or strategy

This document describes the evidence that has been considered by NHS England in formulating a policy to routinely commission pasireotide diaspartate in the treatment of Cushing’s disease.

Document

clin-comm-pol-16052p

PDF
482 KB
16 pages

Cookies on the NHS England website

clin-comm-pol-16052p